Navigation Links
QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Date:7/26/2010

ds to directly commercialise its products in the US and seek strategic partnerships for worldwide markets. QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. Data collected from these studies provided additional guidance for optimising the design and initiation of two pivotal Phase 3 studies required for New Drug Application (NDA) filings with the US Food and Drug Administration (FDA). QRxPharma expects to complete its Phase 3 program Q4 2010 and submit its New Drug Application (NDA) for MoxDuo®IR to the FDA in Q1 2011. No additional pharmacology, toxicology or long-term clinical safety studies will likely be required for regulatory submission. The Company's preclinical and clinical pipeline includes MoxDuo®IV and MoxDuo®CR, plus other technologies in the fields of neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.


'/>"/>
SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... BIRMINGHAM, Ala., June 8, 2011 SANYO North ... its Cell Processing Work Station (CPWS), an integrated, stand-alone ... stem cell and cell therapies for research use, has ... (UAB) as the nation,s first installation of the CPWS, ...
... 2011 According to a report published today by ... has begun to adapt to stricter governmental brand name ... it files for every new drug. These newer standards ... European Medicines Agency (EMA) are part of an effort ...
Cached Medicine Technology:SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 2SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 3Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 2Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 3
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
(Date:7/10/2014)... of electronic health record becomes widespread across the United ... Affordable Care Act, the quantity of clinical data that ... also dramatically increase. Additionally, experts in healthcare have ... quantities of data for the purpose of gleaning insights ... patient care a process that is known as ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... -- Men who have a vasectomy may be at ... suggests. But the risk is comparatively small, the ... study said more research is needed to determine if ... study, Harvard researchers analyzed data from more than 49,400 ... in 1986. During that time, 6,023 cases of prostate ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3
... simple magnetic resonance imaging (MRI) test involving breathing oxygen might ... report researchers at UT Southwestern Medical Center. Prior ... a tumor can be a predictor of how well a ... to grow stronger and resist both radiotherapy and chemotherapy. Until ...
... be attributed to the American Chemistry Council (ACC): , ... (ACC) today welcomed a congressional request to the Food and ... evidence on the safety of bisphenol A (BPA) in food-contact ... Henry Waxman and Bart Stupak that an immediate, transparent assessment ...
... dollars in lost productivity annually, according to a ... School of School of Public Health, the International ... South Wales and the African Vision Research Institute. ... suffer with vision impairment resulting from uncorrected refractive ...
... Bus Shelters throughout Washington and Companion TV Spot Highlight CDC,s Failure ... , , HIV Prevalence Rate in Washington ... Lagos , Nigeria , , WASHINGTON, ... through which it highlights the Centers for Disease Control,s (CDC) failure ...
... more than 25 years of experience to support growing ... N.J., June 2 Covance Inc. today announced Monte ... biostatistics for periapproval services. With more than 25 ... and global data management, Jarvis will oversee data management ...
... Medical International Technology Inc. (MDLH.PK) ( http://www.mitcanada.ca ... Mr. Michel Bayouk, our former Corporate Secretary, Principal Accounting ... Michel Bayouk tendered his resignation from Medical International Technology ... officer due to health related reasons. , June 1st ...
Cached Medicine News:Health News:Oxygen + MRI might help determine cancer therapy success, researchers find 2Health News:American Chemistry Council Welcomes Call for Expedited FDA Review of BPA 2Health News:Vision impairment costs billions lost in productivity 2Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 2Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 3Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 4Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 2Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 3Health News:Mr. Michel Bayouk resignation and passing 2
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... Reviews enable all those involved with healthcare ... the very latest evidence in their field ... harder each year as the volume of ... by delivering the best single source available ...
Muscles Anatomy Flash Cards uses the time tested content and images from BryanEdwards.com....
Medicine Products: